

PART B - FEE(S) TRANSMITTAL

Complete and send this form, together with applicable fee(s), to: **Mail**

**Mail Stop ISSUE FEE
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450
(703) 746-4000**

or **Fax**

INSTRUCTIONS: This form should be used for transmitting the ISSUE FEE and PUBLICATION FEE (if required). Blocks 1 through 4 should be completed where appropriate. All further correspondence including the Patent, advance orders and notification of maintenance fees will be mailed to the current correspondence address as indicated unless corrected below or directed otherwise in Block 1, by (a) specifying a new correspondence address; and/or (b) indicating a separate "FEE ADDRESS" for maintenance fee notifications.

CURRENT CORRESPONDENCE ADDRESS (Note: Legibly mark-up with any corrections or use Block 1)

Note: A certificate of mailing can only be used for domestic mailings of the Fee(s) Transmittal. This certificate cannot be used for any other accompanying papers. Each additional paper, such as an assignment or formal drawing, must have its own certificate of mailing or transmission.

Express Label EV512402362US

Certificate of Mailing or Transmission

I hereby certify that this Fee(s) Transmittal is being deposited with the United States Postal Service with sufficient postage for first class mail in an envelope addressed to the Mail Stop ISSUE FEE address above, or being facsimile transmitted to the USPTO, on the date indicated below.

Sean Hunziker	(Depositor's name)
<i>Sean Hunziker</i>	(Signature)
July 9, 2004	(Date)

7590 06/02/2004
INTELLECTUAL PROPERTY GROUP
MILLENNIUM PHARMACEUTICALS INC.
~~75 HUNTER STREET~~ 40 Landsdowne Street
CAMBRIDGE, MA 02139



APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
-----------------	-------------	----------------------	---------------------	------------------

09/875,321 06/06/2001 Rory A.J. Curtis 10448-061001 / 7512

TITLE OF INVENTION: 52906, 33408, AND 12189, NOVEL POTASSIUM CHANNEL FAMILY MEMBERS AND USES THEREOF

APPLN. TYPE	SMALL ENTITY	ISSUE FEE	PUBLICATION FEE	TOTAL FEE(S) DUE	DATE DUE
-------------	--------------	-----------	-----------------	------------------	----------

nonprovisional NO \$1330 \$300 \$1630 09/02/2004

EXAMINER	ART UNIT	CLASS-SUBCLASS
----------	----------	----------------

PAK, MICHAEL D 1646 435-006000

1. Change of correspondence address or indication of "Fee Address" (37 CFR 1.363).

- ☐ Change of correspondence address (or Change of Correspondence Address form PTO/SB/122) attached.
☐ "Fee Address" indication (or "Fee Address" Indication form PTO/SB/47; Rev 03-02 or more recent) attached. **Use of a Customer Number is required.**

2. For printing on the patent front page, list (1) the names of up to 3 registered patent attorneys or agents OR, alternatively, (2) the name of a single firm (having as a member a registered attorney or agent) and the names of up to 2 registered patent attorneys or agents. If no name is listed, no name will be printed.

1 Millennium Pharmaceuticals, Inc.
2 _____
3 _____

3. ASSIGNEE NAME AND RESIDENCE DATA TO BE PRINTED ON THE PATENT (print or type)

PLEASE NOTE: Unless an assignee is identified below, no assignee data will appear on the patent. Inclusion of assignee data is only appropriate when an assignment has been previously submitted to the USPTO or is being submitted under separate cover. Completion of this form is NOT a substitute for filing an assignment.

(A) NAME OF ASSIGNEE

(B) RESIDENCE: (CITY and STATE OR COUNTRY)

Millennium Pharmaceuticals, Inc. Cambridge, Massachusetts

Please check the appropriate assignee category or categories (will not be printed on the patent); ☐ individual ☒ corporation or other private group entity ☐ government

4a. The following fee(s) are enclosed:

- ☒ Issue Fee
☒ Publication Fee
☒ Advance Order - # of Copies 3

4b. Payment of Fee(s):

- ☐ A check in the amount of the fee(s) is enclosed.
☐ Payment by credit card. Form PTO-2038 is attached.
☒ The Director is hereby authorized by charge the required fee(s), or credit any overpayment, to Deposit Account Number 501668 (enclose an extra copy of this form).

Director for Patents is requested to apply the Issue Fee and Publication Fee (if any) or to re-apply any previously paid issue fee to the application identified above.

(Authorized Signature) <i>Kerri Pollard Schray</i>	(Date) 7/9/04
Kerri Pollard Schray, Reg. No. 47,066	
NOTE: The Issue Fee and Publication Fee (if required) will not be accepted from anyone other than the applicant; a registered attorney or agent; or the assignee or other party in interest as shown by the records of the United States Patent and Trademark Office.	
This collection of information is required by 37 CFR 1.311. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Alexandria, Virginia 22313-1450.	
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.	

07/13/2004 HDEMESS2 00000028 501668 09875321
01 FC:1501 1330.00 DA
02 FC:1504 300.00 DA
03 FC:8001 9.00 DA

TRANSMIT THIS FORM WITH FEE(S)



Practitioner's Docket No. MPI00-252P1RM

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: **Curtis, Rory A.J.**
Application No.: **09/875,321** Group No.: **1646**
Filed: **June 6, 2001** Examiner: **PAK, Michael D.**
For: **52906, 33408, AND 12189, NOVEL POTASSIUM CHANNEL FAMILY MEMBERS
AND USES THEREOF**

Mail Stop Issue Fee
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Confirmation No. 7512

TRANSMITTAL

1. Transmitted herewith for this application is/are:
- a. This Transmittal (1 page - in duplicate);
 - b. Transmittal of Payment of Issue Fee (1 page - in duplicate);
 - c. Part B - Fees Transmittal (1 page - in duplicate); and
 - d. Return Postcard.

STATUS


2. Applicant is other than a small entity.

FEE DEFICIENCY

3. If any additional extension and/or fee is required, charge Account No. 501668.
If any additional fee for claims is required, charge Account No. 501668.

July 9, 2004

MILLENNIUM PHARMACEUTICALS, INC.

By 
Kerri Pollard Schray
Reg. No. 47,066
40 Landsdowne Street
Cambridge, MA 02139
Telephone - (617) 551-3676
Facsimile - (617) 551-8820

CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10*

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

- ☒ deposited with the United States Postal Service in an envelope addressed to Mail Stop Issue Fee, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.
37 C.F.R. SECTION 1.8(a)


37 C.F.R. SECTION 1.10*

- ☐ with sufficient postage as first class mail. ☒ as "Express Mail Post Office to Addressee"
Mailing Label No. EV512402362US

TRANSMISSION

- ☐ transmitted by facsimile to the Patent and Trademark Office.

Date: July 9, 2004


Signature
Sean Hunziker
(type or print name of person certifying)

***WARNING:** Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.



Practitioner's Docket No. MPI00-252P1RM

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Re application of: Curtis, Rory A.J.

Application No.: 09/875,321

Group No.: 1646

Filed: June 6, 2001

Examiner: PAK, Michael D.

For: 52906, 33408, AND 12189, NOVEL POTASSIUM CHANNEL FAMILY MEMBERS
AND USES THEREOF

Mail Stop Issue Fee

Confirmation No. 7512

Commissioner for Patents

P.O. Box 1450


Alexandria, VA 22313-1450

TRANSMITTAL OF PAYMENT OF ISSUE FEE (37 C.F.R. SECTION 1.311)

1. Applicant hereby pays the issue fee for the attached Issue Fee Transmittal PTOL-85.
2. Fee (37 C.F.R. Section 1.18(a)):

Regular

Application status is other than a small entity--fee: \$1,330.00
3. Payment of fee: Charge Account No. 501668 the sum of \$1,639.00 (includes Issue Fee of \$1,330.00, Publication Fee of \$300, and Fee of \$9.00 for 3 soft copies.)
(A duplicate of this request is attached.)

<u>July 9, 2004</u>	MILLENNIUM PHARMACEUTICALS, INC. By <u></u> Kerri Pollard Schray Reg. No. 47,066 40 Landsdowne Street Cambridge, MA 02139 Telephone - (617) 551-3676 Facsimile - (617) 551-8820
---------------------	---

CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10*

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

- ☒ deposited with the United States Postal Service in an envelope addressed to Mail Stop Issue Fee, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.
37 C.F.R. SECTION 1.8(a)

37 C.F.R. SECTION 1.10*

- ☐ with sufficient postage as first class mail.

☒ as "Express Mail Post Office to Addressee"
Mailing Label No. EV512402362US

TRANSMISSION

- ☐ transmitted by facsimile to the Patent and Trademark Office.

Date: July 9, 2004


Signature

Sean Hunziker

(type or print name of person certifying)

***WARNING:** Each paper or fee filed by "Express Mail" **must** have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will **not** be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.